Wirkstoff:
Tecentriq 1200 MG in 20 ML Injection, H3K27M peptide vaccine
Indikation (Clinical Trials):
Glioma
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 1
Sponsor:
German Cancer Research Center
Collaborator:
Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid,
Studienleiter
Michael Platten, Prof. Principal Investigator German Cancer Research Center Germany
Kontakt
Michael Platten, Prof. Kontakt: Phone: 49 621 383 2885 E-Mail: m.platten@Dkfz-Heidelberg.de» Kontaktdaten anzeigen
Studienlocations (3 von 8)
University Medical Center Mannheim, Department of Neurology 68167 Mannheim (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: Michael Platten, Prof Dr» Ansprechpartner anzeigenUniversity Clinic Tuebingen, Neurological Clinic, Department of Neurology 72076 Tuebingen (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: Ghazaleh Tabatabai, Prof Dr» Ansprechpartner anzeigenDepartment of Neurology and Polyclinic, Universitiy Clinic Heidelberg 69120 Heidelberg (Baden-Württemberg) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Antje Wick, PD. Dr. med.» Ansprechpartner anzeigen
Dr. Senckenberg Institute for Neurooncology, University Hospital Frankfurt 60528 Frankfurt am Main (Hessen) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Michael Ronellenfitsch, PD Dr. med. Dr. rer. nat.» Ansprechpartner anzeigenClinical Neuro-Oncology Section, University Hospital Bonn (UKB) 53127 Bonn (Nordrhein-Westfalen) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Ulrich Herrlinger, Prof. Dr. med.» Ansprechpartner anzeigenNeurooncology Department, University Hospital Essen 45147 Essen (Nordrhein-Westfalen) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Martin Glas, Prof. Dr. med.» Ansprechpartner anzeigenClinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden 1307 Dresden (Sachsen) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Dietmar Krex, Prof. Dr. med.» Ansprechpartner anzeigenDepartment of Neurosurgery with Pediatric Neurosurgery 10117 Berlin (Berlin) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Peter Vajkoczy, Prof. Dr. med.» Ansprechpartner anzeigen
1. Assessment of safety of repeated fixed dose vaccinations with the H3K27M peptide vaccine administered with radiotherapy and Atezolizumab in patients with H3K27M-mutant gliomas. Primary safety endpoint is the Regime Limiting Toxicity (RLT). (Time Frame - Through study completion, an average of one year): Safety of H3K27M peptide vaccine administered with radiotherapy and Atezolizumab. Primary safety endpoint is the Regime Limiting Toxicity (RLT).
2. Assessment of immunogenicity of repeated fixed dose vaccinations with the H3K27M peptide vaccine administered with radiotherapy and Atezolizumab in patients with H3K27M-mutant gliomas. (Time Frame - From Day 1 until the date of study termination (until day 540); approximately 16 times): Immunogenicity (Immune response Yes/No) will be assessed for all evaluable patients. The primary immunogenicity endpoint is the presence of an H3K27M-specific T-cell response. H3K27M-specific T cell responses are measured on Peripheral Blood Mononuclear Cells (PBMC) using IFN-gamma ELISpot.
Secondary outcome:
1. Progression-free survival (PFS) (Time Frame - From day of first diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to the date of study termination (approximately until day 540)): PFS, defined as time from the day of first diagnosis to the day of local tumor progression or the day of death of any cause (whichever occurs first), censored by the end of the observation. PFS analysis will be based on the central disease assessment (refer to section 7.5.1). Patients lacking an evaluation of tumor response (based on radiological or clinical assessment) will have their PFS time censored on the date of first diagnosis with duration of 1 day.
2. Overall response rate (ORR) (Time Frame - Baseline visit to end of study (approximately until day 540)): ORR, defined as the proportion of patients showing complete response (CR), partial response (PR) or stable disease (SD) at EOS compared to the baseline value (MRI at visit 1 for ORR under trial drug). ORR analysis will be based on the central disease assessment according to the iRANO criteria.
3. Analyze the association between immunogenicity and the clinical outcome parameters ORR (Time Frame - Through study completion, an average of one year)
4. Analyze the association between immunogenicity and the clinical outcome parameters PFS (Time Frame - Through study completion, an average of one year)
Tecentriq 1200 MG in 20 ML Injection (Atezolizumab): One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
H3K27M peptide vaccine: The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
Imiquimod (5%) (Aldara): One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!